Protective Effects of Glurenorm (gliquidone) Treatment on the Liver Injury of Experimental Diabetes

Oxidative stress plays an important role in chronic complications of diabetes mellitus, and hence the regulation of free radicals is essential in the treatment of diabetes. The aim of the current study is to investigate the effect of glurenorm (10 mg/kg) on liver tissue in experimental diabetes. Diabetes was induced by intraperitoneal injection of 65 mg/kg streptozotocin. Glurenorm was administered to one diabetic and one control group separately, from days 14 to 42. On day 42, cardiac blood samples and liver tissue were taken from each rat. In diabetic rats, blood glucose, serum alkaline phosphatase and serum amino transferase activities, serum uric acid, serum sodium and potassium levels, liver nonenzymatic glycosylation, and lipid peroxidation increased, whereas body weight and liver glutathione levels decreased. The diabetic group given glurenorm blood glucose, serum alkaline phosphatase and aminotransferase activities, serum uric acid, sodium and potassium, liver nonenzymatic glycosylation, and lipid peroxidation levels decreased, and liver glutathione levels increased. As a result of all the biochemical findings obtained, it was concluded that glurenorm has a protective effect on damage of liver of streptozotocin-induced diabetes in rats.